Hey everyone, Just wanted to share an important message that Jeff Cohen put out from their firm's TikTok account this morning. For those who don't know, Jeff represents some major companies in the peptide space, so when he speaks, it's worth paying attention. Please watch the full video - I don't like to put words in anyone's mouth, and the full context matters here. From what I'm seeing, my assumptions seem to be correct that something bigger is coming. This isn't just about FDA 66-80 or the SAFE Drug Act - there appears to be something specifically targeting the research space as well. I know regulatory uncertainty is stressful for all of us, but staying informed is our best defense. As always, I will keep everyone in the loop as I learn more. Drop your thoughts below after watching 👇

Do your research subjects experience a crash around day 6 or 7? It's a common pattern researchers observe... Days 1-4: Strong response. Minimal appetite signaling. Low food-seeking behavior. Days 5-6: Effects softening. Appetite signals returning. Day 7: Significant hunger response. Waiting on next administration. This isn't a flaw in the research protocol. It's basic pharmacokinetics. Here's what the data shows: Even with tirzepatide's ~5-day half-life, by day 7, circulating levels drop to roughly 60-65% of peak concentration. Receptor occupancy decreases proportionally. But what if you could maintain more stable levels throughout the research period? Same total weekly dose. Same mg. Just redistributed. → Reduced peak-related side effects → No end-of-week trough effects → More consistent receptor activation → Flatter concentration curve I wrote a deep dive breaking down: ✓ Why these compounds accumulate and why dose increases before week 4 skew results ✓ The math behind steady state ✓ Why clinical trials use once-weekly protocols (hint: it's about adherence, not optimization) ✓ Which research scenarios benefit from split dosing ✓ Practical protocols and considerations Full article with all the mechanisms 👇 https://open.substack.com/pub/derekpruski/p/split-dosing-glp-1s-why-smaller-more?utm_campaign=post-expanded-share&utm_medium=web Drop a comment if you've experimented with split dosing in your research—curious what others have observed.